Comparative in silico analysis of two vaccine candidates for group A streptococcus predicts that they both may have similar safety profiles.
Concerns of immune cross-reactivity, between epitopes of the group A streptococcal (GAS) M-proteins and host proteins have hindered the progress of an effective GAS vaccine. An ideal M-protein based subunit vaccine should not elicit heart tissue cross-reactive antibody responses and should not activate M-protein specific CD4+ T-cells. In the current study we used a bioinformatic and immunoinformatic approach to assess the safety of J8 and J14, chimeric vaccine constructs containing a GAS derived M-protein epitope embedded in flanking GCN4 region. We demonstrate that at the primary amino acid level J8 and J14 show very little homology to human proteins. ProPred, RANKPEP and HLABIND algorithms failed to predict significant binding between the M-protein specific regions of J8 and J14 and class II binding alleles. A single peptide was predicted to bind to HLA class I allele B_2705. This data was supported by cellular proliferation assays demonstrating few peripheral blood mononuclear cells (PBMCs) from donors respond to J8 and J14. Reassuringly, there was no correlation between proliferation to these peptides, and proliferation to host proteins. This data suggests that J8 and J14 are unlikely to induce cross-reactive immune responses, and will be safe for use in humans.
Shaila
Melkote S
MS
Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.
Nayak
Rabindranath
R
Prakash
Savitha S
SS
Georgousakis
Melina
M
Brandt
Evelyn
E
McMillan
David J
DJ
Batzloff
Michael R
MR
Pruksakorn
Sumalee
S
Good
Michael F
MF
Sriprakash
Kadaba S
KS
D000595:Amino Acid Sequence; D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology; D000942:Antigens, Bacterial / Q000009:adverse effects / Q000737:chemistry* / Q000235:genetics / Q000276:immunology; D001425:Bacterial Outer Membrane Proteins / Q000009:adverse effects / Q000737:chemistry* / Q000235:genetics / Q000276:immunology; D050976:Basic-Leucine Zipper Transcription Factors; D001782:Blood Donors; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D002352:Carrier Proteins / Q000009:adverse effects / Q000737:chemistry* / Q000235:genetics / Q000276:immunology; D019295:Computational Biology; D003429:Cross Reactions; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism; D000939:Epitopes; D015395:Histocompatibility Antigens Class I / Q000378:metabolism; D000949:Histocompatibility Antigens Class II / Q000378:metabolism; D006801:Humans; D008213:Lymphocyte Activation / Q000276:immunology*; D010455:Peptides / Q000737:chemistry*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D029701:Saccharomyces cerevisiae Proteins / Q000235:genetics / Q000378:metabolism; D022541:Streptococcal Vaccines / Q000009:adverse effects*; D013297:Streptococcus pyogenes / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins; D050976:Basic-Leucine Zipper Transcription Factors; D002352:Carrier Proteins; D004268:DNA-Binding Proteins; D000939:Epitopes; C501391:GCN4 protein, S cerevisiae; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D010455:Peptides; D011993:Recombinant Fusion Proteins; D029701:Saccharomyces cerevisiae Proteins; D022541:Streptococcal Vaccines; D014157:Transcription Factors; C014689:streptococcal M protein